Log In
Print this Print this

ALKS 4230 (formerly RDB 1419, RDB 1450)

  Manage Alerts
Collapse Summary General Information
Company Alkermes plc
DescriptionFusion protein of circularly permuted IL-2 and IL-2 receptor alpha chain (CD25) that activates and increases the number of immunostimulatory tumor-killing immune cells
Molecular Target Interleukin-2 (IL-2) receptor beta chain (CD122) (IL2RB) ; Interleukin-2 (IL-2) receptor gamma chain (IL2RG) (CD132)
Mechanism of ActionInterleukin-2 (IL-2) receptor agonist
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today